United Therapeutics (UTHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The medical devices and novel treatments United Therapeutics Corporation (UTHR) develops to treat pulmonary arterial hypertension (PAH) and other ailments are attracting substantial Big Money investment.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.